Vimarsana
Biggest News Aggregation in the World

Barney Liu News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Barney Liu. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Barney Liu Today - Breaking & Trending Today

Investegate |BioNTech SE Announcements | BioNTech SE: BioNTech and Fosun Pharma Provide COVID-19 Vaccine Doses For Vaccination of German Expatriates in China - Vimarsana News

Investegate |BioNTech SE Announcements | BioNTech SE: BioNTech and Fosun Pharma Provide COVID-19 Vaccine Doses For Vaccination of German Expatriates in China

Investegate announcements from BioNTech SE, BioNTech and Fosun Pharma Provide COVID-19 Vaccine Doses For Vaccination of German Expatriates in China

BioNTech SE: BioNTech and Fosun Pharma Provide COVID-19 Vaccine Doses For Vaccination of German Expatriates in China - Vimarsana News

BioNTech SE: BioNTech and Fosun Pharma Provide COVID-19 Vaccine Doses For Vaccination of German Expatriates in China

Approximately 11,500 of the companies' mRNA-based COVID-19 vaccine doses arrived on the Chinese Mainland to enable vaccination campaign for German expatriatesVaccines expected to be available in Beijing

BioNTech SE: BioNTech and Fosun Pharma to Supply China with mRNA-based COVID-19 Vaccine - Vimarsana News

BioNTech SE: BioNTech and Fosun Pharma to Supply China with mRNA-based COVID-19 Vaccine

BioNTech SE: BioNTech and Fosun Pharma to Supply China with mRNA-based COVID-19 Vaccine A local Phase 2 clinical trial of mRNA COVID-19 vaccine candidate BNT162b2 is on-going in Jiangsu, China MAINZ, GERMANY, and SHANGHAI, CHINA, December 16, 2020("Fosun Pharma" or "Group"; Stock Code: 600196.SH, 02196.HK) today announced an agreement to supply Mainland China with an initial 100 million doses of their BNT162 mRNA-based vaccine candidate against COVID-19 in 2021, subject to regulatory approval. Initial supply will be delivered from BioNTech's production facilities in Germany. "We would like t...